Merck & Co., Inc. $MRK Stock: HighTower Advisors LLC Lowers Position

HighTower Advisors LLC lessened its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,409,160 shares of the company’s stock after selling 270,760 shares during the period. HighTower Advisors LLC owned about 0.14% of Merck & Co., Inc. worth $495,385,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of MRK. Vestor Capital LLC boosted its stake in Merck & Co., Inc. by 16,530.7% in the 3rd quarter. Vestor Capital LLC now owns 27,607 shares of the company’s stock worth $4,012,000 after buying an additional 27,441 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $11,470,000. Russell Investments Group Ltd. lifted its holdings in shares of Merck & Co., Inc. by 2.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after acquiring an additional 51,393 shares during the period. Cardinal Capital Management lifted its holdings in shares of Merck & Co., Inc. by 3.6% during the 3rd quarter. Cardinal Capital Management now owns 99,742 shares of the company’s stock worth $14,578,000 after acquiring an additional 3,507 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Merck & Co., Inc. by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company’s stock worth $266,403,000 after acquiring an additional 227,589 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president directly owned 112,955 shares of the company’s stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the subject of a number of recent analyst reports. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a report on Wednesday, August 12th. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Monday, October 19th. Argus started coverage on shares of Merck & Co., Inc. in a research note on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. HSBC lifted their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Royal Bank Of Canada lowered their price objective on shares of Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $155.74.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $144.49 on Tuesday. The firm has a market capitalization of $356.20 billion, a P/E ratio of 148.96, a P/E/G ratio of 6.74 and a beta of 0.13. Merck & Co., Inc. has a 1-year low of $92.11 and a 1-year high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The business’s 50-day simple moving average is $146.04 and its 200-day simple moving average is $128.80.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter in the previous year, the business earned $2.58 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.